SCHEMBL6489077

SCHEMBL6489077

O=C(Nc1ccc(Cl)c(Cl)c1)Nc1ccccc1CCO

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 7/20 0.74
MEN1 O00255 6/20 0.64
KMT2A Q03164 6/20 0.64
NPC1 O15118 4/20 0.64
RAB9A P51151 3/20 0.64
MAPT P10636 3/20 0.64
POLB P06746 1/20 0.64
GAA P10253 1/20 0.64
ALDH1A1 P00352 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
KDM4E B2RXH2 1/20 0.61
NFKB1 P19838 1/20 0.61
GFER P55789 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
MAPK14 Q16539 1/20 0.60
EPHX1 P07099 2/20 0.59
EPHX2 P34913 2/20 0.59
LMNA P02545 2/20 0.54
HTT P42858 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478147 0.85 TRPV1 (0.65) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL30792273 0.84 TRPV1 (0.63) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL23831812 0.84 TRPV1 (0.63) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL23831565 0.83 TRPV1 (0.62) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL6480232 0.82 TRPV1 (0.62) TRPV1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1626521 0.81 TRPV1 (0.50) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL30104873 0.81 TRPV1 (0.60) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL23831645 0.81 TRPV1 (0.60) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL8208060 0.81 MEN1 (0.77) TRPV1MEN1KMT2ANPC1RAB9A
SCHEMBL23831594 0.81 TRPV1 (0.60) TRPV1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154230-A1 Urea derivatives BAYER HEALTHCARE AG (DE) 2005-07-14 US disclosed
EP-1461311-A2 UREA DERIVATIVES AS VR1-ANTAGONISTS Bayer HealthCare AG (DE) 2004-09-29 EP disclosed
WO-2003055848-A2 UREA DERIVATIVES AS VR1- ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-07-10 WO disclosed
JP-2003192659-A PHENYLUREA DERIVATIVE BAYER AG 2003-07-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154230-A1 Urea derivatives SLC14A1, UBA1, VAT1 TRPV1 214/4885MEN1 4397/4885KMT2A 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.